Purespring raises £80m to target kidney disease

Quick Summary:

Listed firm Syncona committed £19.9m as part of a syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion and British Patient Capital.

Having sophisticated, experienced and committed investors on board, who understand drug development and the urgency of bringing these much-needed therapies to patients will maximise the opportunities for the company and the patients we treat.

The company has generated encouraging pre-clinical data validating the therapeutic potential of its technology and has developed a strong chemistry, manufacturing and controls platform that it says will support future clinical development and commercialisation.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Jonathan Symcox

Category: InvestingBusiness

Markets: United Kingdom

Topics: MedTech Investment

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-10-09 @ 15:32:07 (14 hours ago)

News Timezone: GMT +8:00

News Source URL: businesscloud.co.uk

Language: English

Article Length: 416 words

Reading Time: 3 minutes read

Sentences: 12 lines

Sentence Length: 35 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © BusinessCloud

News ID: 22969912

View Article Analysis

About BusinessCloud

Main Topics: InvestingBusiness

Official Website: businesscloud.co.uk

Update Frequency: 5 posts per day

Year Established: 2016

Headquarters: United Kingdom

News Last Updated: 22 hours ago

Coverage Areas: United Kingdom

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #61

Publisher Details

Frequently Asked Questions